Inflammation in neurodegenerative diseases - an update

Immunology

Volumn 142, Issue 2, 2014, Pages 151-166

  Amor, Sandra ^a,b   Peferoen, Laura A N ^a   Vogel, Daphne Y S ^a   Breur, Marjolein ^a   van der Valk, Paul ^a   Baker, David ^b   Van Noort, Johannes M ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Delta Crystallon BV   (Netherlands)

Author keywords

Central nervous system; Inflammation; Innate; Neurodegeneration; Neuroprotection; Repair

Indexed keywords

METAL;

ADAPTIVE IMMUNITY; AGING; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; ECONOMIC ASPECT; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INNATE IMMUNITY; MOLECULAR INTERACTION; NERVE DEGENERATION; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT;

CENTRAL NERVOUS SYSTEM; INFLAMMATION; INNATE; NEURODEGENERATION; NEUROPROTECTION; REPAIR;

HUMANS; INFLAMMATION; NEURODEGENERATIVE DISEASES;

EID: 84899062441     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12233     Document Type: Review

References (109)

1. World Health Organization. Dementia a public health priority. [Geneva]:: World Health Organization 2012. http://site.ebrary.com/lib/ucmerced/Doc?id=10718026 [accessed 14 November 2013].
2. Amor S, Puentes F, Baker D et al. Inflammation in neurodegenerative diseases. Immunology 2010; 129:154-69.
3. Town T, Tan J, Flavell RA et al. T-cells in Alzheimer's disease. Neuromolecular Med 2005; 7:255-64.
4. Bellucci A, Bugiani O, Ghetti B et al. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis 2011; 8:221-9.
5. Mosley RL, Hutter-Saunders JA, Stone DK et al. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2:a009381.
6. Maetzler W, Berg D, Synofzik M et al. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 2011; 26:171-9.
7. Ellrichmann G, Reick C, Saft C et al. The role of the immune system in Huntington's disease. Clin Dev Immunol 2013; 2013:541259.
8. Papadimitriou D, Le Verche V, Jacquier A et al. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis 2010; 37:493-502.
9. Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007; 10:1355-60.
10. Melzer N, Meuth SG, Wiendl H. Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. Curr Opin Neurol 2012; 25:341-8.
11. Zuliani L, Graus F, Giometto B et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatr 2012; 83:638-45.
12. Archer LD, Langford-Smith KJ, Bigger BW et al. Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis 2014; 37:1-12.
13. Sta M, Sylva-Steenland RMR, Casula M et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 2011; 42:211-20.
14. Puentes F, Topping J, Kuhle J et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatr 2013. doi:10.1136/jnnp-2013-305494.
15. Podda G, Nyirenda M, Crooks J et al. Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis. J Neuroimmune Pharmacol 2013; 8:791-806.
16. Van Noort JM, Baker D, Amor S. Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors. CNS Neurol Disord Drug Targets 2012; 11:556-69.
17. Van der Valk P, Amor S. Preactive lesions in multiple sclerosis. Curr Opin Neurol 2009; 22:207-13.
18. Van Noort JM, Bsibsi M, Gerritsen WH et al. α-B-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol 2010; 69:694-703.
19. Saji E, Arakawa M, Yanagawa K et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 2013; 73:65-76.
20. Mitsdoerffer M, Kuchroo V, Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 2013; 1283:57-66.
21. Bradford BM, Mabbott NA. Prion disease and the innate immune system. Viruses 2012; 4:3389-419.
22. Kraft AD, Harry GJ. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 2011; 8:2980-3018.
23. Chamorro Á, Meisel A, Planas AM et al. The immunology of acute stroke. Nat Rev Neurol 2012; 8:401-10.
24. Brait VH, Arumugam TV, Drummond GR et al. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab 2012; 32:598-611.
25. Bauer J, Vezzani A, Bien CG. Epileptic encephalitis: the role of the innate and adaptive immune system. Brain Pathol 2012; 22:412-21.
26. Das M, Mohapatra S, Mohapatra SS. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation 2012; 9:236.
27. Locatelli G, Wörtge S, Buch T et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci 2012; 15:543-50.
28. Hoarau J-J, Krejbich-Trotot P, Jaffar-Bandjee M-C et al. Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol Disord Drug Targets 2011; 10:25-43.
29. Kierdorf K, Prinz M. Factors regulating microglia activation. Front Cell Neurosci 2013; 7:44.
30. Peferoen L, Kipp M, van der Valk P et al. Oligodendrocyte-microglia cross-talk in the CNS. Immunology 2013; 141:302-13.
31. Goldbaum O, Richter-Landsberg C. Stress proteins in oligodendrocytes: differential effects of heat shock and oxidative stress. J Neurochem 2001; 78:1233-42.
32. Toguchi M, Gonzalez D, Furukawa S et al. Involvement of Sema4D in the control of microglia activation. Neurochem Int 2009; 55:573-80.
33. Okada A, Tominaga M, Horiuchi M et al. Plexin-A4 is expressed in oligodendrocyte precursor cells and acts as a mediator of semaphorin signals. Biochem Biophys Res Commun 2007; 352:158-63.
34. Tian L, Lappalainen J, Autero M et al. Shedded neuronal ICAM-5 suppresses T-cell activation. Blood 2008; 111:3615-25.
35. Wang Y, Szretter KJ, Vermi W et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol 2012; 13:753-60.
36. Mott RT, Ait-Ghezala G, Town T et al. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 2004; 46:369-79.
37. Chavarría A, Cárdenas G. Neuronal influence behind the central nervous system regulation of the immune cells. Front Integr Neurosci 2013; 7:64.
38. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology 2013; 141:314-27.
39. Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol 2013; 13:551-65.
40. Bsibsi M, Holtman IR, Gerritsen WH et al. α-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol 2013; 72:970-9.
41. Bsibsi M, Persoon-Deen C, Verwer RWH et al. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 2006; 53:688-95.
42. Lee J-E, Han P-L. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol 2013; 22:84-95.
43. Shimada A, Hasegawa-Ishii S. Senescence-accelerated mice (SAMs) as a model for brain aging and immunosenescence. Aging Dis 2011; 2:414-35.
44. Moser JM, Bigini P, Schmitt-John T. The wobbler mouse, an ALS animal model. Mol Genet Genomics 2013; 288:207-29.
45. Figiel M, Szlachcic WJ, Switonski PM et al. Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol 2012; 46:393-429.
46. Blesa J, Phani S, Jackson-Lewis V et al. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012; 2012:845618.
47. Wadsworth JDF, Asante EA, Collinge J. Review: contribution of transgenic models to understanding human prion disease. Neuropathol Appl Neurobiol 2010; 36:576-97.
48. Macrae IM. Preclinical stroke research-advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol 2011; 164:1062-78.
49. Van der Star BJ, Vogel DYS, Kipp M et al. In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets 2012; 11:570-88.
50. Amor S, Smith PA, Hart B' et al. Biozzi mice: of mice and human neurological diseases. J Neuroimmunol 2005; 165:1-10.
51. Bajramovic JJ. Regulation of innate immune responses in the central nervous system. CNS Neurol Disord Drug Targets 2011; 10:4-24.
52. Shook BC, Jackson PF. Adenosine A(2A) receptor antagonists and Parkinson's disease. ACS Chem Neurosci 2011; 2:555-67.
53. Brennan FH, Anderson AJ, Taylor SM et al. Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation 2012; 9:137.
54. Fisher Y, Nemirovsky A, Baron R et al. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS One 2010; 5:e10830.
55. Zhang J, Ke K-F, Liu Z et al. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of aβ1-42-induced Alzheimer's disease model rats. PLoS One 2013; 8:e75786.
56. Puentes F, van der Star BJ, Victor M et al. Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis. J Neuroinflammation 2013; 10:118.
57. Huizinga R, Gerritsen W, Heijmans N et al. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 2008; 32:461-70.
58. Srivastava R, Aslam M, Kalluri SR et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367:115-23.
59. Kusunoki S. Autoantibodies in neuroimmunological diseases; relevance of fine specificity. Exp Neurol 2013; 250C:219-20.
60. Lassmann H, Niedobitek G, Aloisi F et al. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue - report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 2011; 134:2772-86.
61. Peferoen LAN, Lamers F, Lodder LNR et al. Epstein-Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2010; 133:e137.
62. Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol 2010; 120:277-86.
63. Capsoni S, Carucci NM, Cattaneo A. Pathogen free conditions slow the onset of neurodegeneration in a mouse model of nerve growth factor deprivation. J Alzheimers Dis 2012; 31:1-6.
64. Bearer EL. HSV, axonal transport and Alzheimer's disease: in vitro and in vivo evidence for causal relationships. Future Virol 2012; 7:885-99.
65. Honjo K, van Reekum R, Verhoeff NPLG. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement 2009; 5:348-60.
66. Miklossy J. Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation 2011; 8:90.
67. Alfahad T, Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res 2013; 99:180-7.
68. Hack N, Jicha GA, Abell A et al. Substantia nigra depigmentation and exposure to encephalitis lethargica. Ann Neurol 2012; 72:912-7.
69. De Chiara G, Marcocci ME, Sgarbanti R et al. Infectious agents and neurodegeneration. Mol Neurobiol 2012; 46:614-38.
70. Virtanen JO, Jacobson S. Viruses and multiple sclerosis. CNS Neurol Disord Drug Targets 2012; 11:528-44.
71. Del Palacio M, Alvarez S, Muñoz-Fernández MÁ. HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol 2012; 22:33-45.
72. Clark KH, Wiley CA, Bradberry CW. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 2013; 23:174-88.
73. Lewis JA, Gehman EA, Baer CE et al. Alterations in gene expression in Caenorhabditis elegans associated with organophosphate pesticide intoxication and recovery. BMC Genomics 2013; 14:291.
74. Kern JK, Geier DA, Audhya T et al. Evidence of parallels between mercury intoxication and the brain pathology in autism. Acta Neurobiol Exp (Wars) 2012; 72:113-53.
75. Harris RA, Amor S. Sweet and sour - oxidative and carbonyl stress in neurological disorders. CNS Neurol Disord Drug Targets 2011; 10:82-107.
76. Laird MD, Shields JS, Sukumari-Ramesh S et al. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia 2014; 62:26-38.
77. Min HJ, Ko EA, Wu J et al. Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates. J Immunol 2013; 190:1797-806.
78. Streit WJ, Xue Q-S. The brain's aging immune system. Aging Dis 2010; 1:254-61.
79. Miron VE, Boyd A, Zhao J-W et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013; 16:1211-8.
80. Goronzy JJ, Li G, Yang Z et al. The janus head of T cell aging - autoimmunity and immunodeficiency. Front Immunol 2013; 4:131.
81. Ajami B, Bennett JL, Krieger C et al. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011; 14:1142-9.
82. Villeda SA, Luo J, Mosher KI et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477:90-4.
83. Biber K, Tsuda M, Tozaki-Saitoh H et al. Neuronal CCL21 up-regulates microglia P2X4 expression and initiates neuropathic pain development. EMBO J 2011; 30:1864-73.
84. Durafourt BA, Moore CS, Zammit DA et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 2012; 60:717-27.
85. Melief J, Koning N, Schuurman KG et al. Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia 2012; 60:1506-17.
86. Elliott C, Lindner M, Arthur A et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012; 135:1819-33.
87. Crehan H, Hardy J, Pocock J. Microglia, Alzheimer's disease, and complement. Int J Alzheimers Dis 2012; 2012:983640.
88. Lee JD, Kamaruzaman NA, Fung JN et al. Dysregulation of the complement cascade in the hsod1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 2013; 10:119.
89. Lobsiger CS, Boillée S, Pozniak C et al. C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc Natl Acad Sci USA 2013; 110:E4385-92.
90. Ramaglia V, King RHM, Morgan BP et al. Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Mol Immunol 2009; 46:1892-6.
91. Schwartz M, Kipnis J, Rivest S et al. How do immune cells support and shape the brain in health, disease, and aging? J Neurosci 2013; 33:17587-96.
92. Gleichman AJ, Carmichael ST. Astrocytic therapies for neuronal repair in stroke. Neurosci Lett 2013. doi:10.1016/j.neulet.2013.10.055
93. White RE, Jakeman LB. Don't fence me in: harnessing the beneficial roles of astrocytes for spinal cord repair. Restor Neurol Neurosci 2008; 26:197-214.
94. Chisholm SP, Cervi AL, Nagpal S et al. Interleukin-17A increases neurite outgrowth from adult postganglionic sympathetic neurons. J Neurosci 2012; 32:1146-55.
95. Kipnis J, Gadani S, Derecki NC. Pro-cognitive properties of T cells. Nat Rev Immunol 2012; 12:663-9.
96. Carson JH, Gao Y, Tatavarty V et al. Multiplexed RNA trafficking in oligodendrocytes and neurons. Biochim Biophys Acta 2008; 1779:453-8.
97. Frühbeis C, Fröhlich D, Kuo WP et al. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol 2013; 11:e1001604.
98. Rajendran L, Honsho M, Zahn TR et al. Alzheimer's disease β-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 2006; 103:11172-7.
99. Jaturapatporn D, Isaac MG, McCleery J et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; 2:CD006378.
100. Castillo-Trivino T, Braithwaite D, Bacchetti P et al. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013; 8:e66308.
101. Li C, Yuan K, Schluesener H. Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis. Rev Neurosci 2013; 24:553-62.
102. Morsali D, Bechtold D, Lee W et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 2013; 136:1067-82.
103. Raftopoulos RE, Kapoor R. Neuroprotection for acute optic neuritis-Can it work? Mult Scler Relat Disord 2013; 2:307-11.
104. Pryce G, Ahmed Z, Hankey DJR et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126:2191-202.
105. Zajicek J, Ball S, Wright D et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013; 12:857-65.
106. Butti E, Bacigaluppi M, Rossi S et al. Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. Brain 2012; 135:3320-35.
107. Pryce G, Baker D. Potential control of multiple sclerosis by cannabis and the endocannabinoid system. CNS Neurol Disord Drug Targets 2012; 11:624-41.
108. Laterza C, Merlini A, De Feo D et al. iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF. Nat Commun 2013; 4:2597.
109. Kokaia Z, Martino G, Schwartz M et al. Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci 2012; 15:1078-87.